Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.42), $0.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $29.09 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• Regional Management (RM) Reiterated at Market Outperform by Citizens After Price Reset